Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from 71% of the analysts covering the stock. With a median price target of $6, the stock has an upside potential of 42.86%.

On December 9, Alec Stranahan from Bank of America Securities reaffirmed a ‘Hold’ rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), while setting a price target of $7, which suggests an upside potential of about 67%.

Just a day earlier, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) revealed its Phase 1b/2 TUPELO trial results for REC-4881, which is an experimental solution for familial adenomatous polyposis (FAP). The results showed that 75% of 12 evaluable patients demonstrated reductions in total polyp burden following 12 weeks of treatment with REC-4881 at 4 mg daily, reporting a median reduction of 43%.

These results were compared to natural history data, outlining that 87% of untreated FAP patients experience yearly increases in polyp burden. With no approved medical therapies as yet, FAP impacts as many as 50,000 individuals in the US and EU5 countries.

Following the findings, Gil Blum, an analyst at Needham, maintained a ‘Buy’ rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), with a price target of $8, on December 8.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a Utah-based clinical-stage biotechnology company specializing in the decoding of biology and chemistry. Founded in 2013, the company develops REC-994, REC-2282, and REC-4881, among others.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.